Related Experiment Video
Updated: Jun 16, 2026
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma
1Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84101, Israel.
Abstract:
This review will focus on recent knowledge related to circulating autoantibodies (AAbs) to tumor-associated antigens (TAAs) in epithelial ovarian carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in epithelial ovarian carcinoma: p53, homeobox proteins (HOXA7, HOXB7), heat shock proteins (HSP-27, HSP-90), cathepsin D, cancer-testis antigens (NY-ESO-1/LAGE-1), MUC1, GIPC-1, IL-8, Ep-CAM, and S100A7. Since AAbs to TAAs have been identified in the circulation of patients with early-stage cancer, it has been speculated that the assessment of a panel of AAbs specific for epithelial ovarian carcinoma TAAs might hold great potential as a novel tool for early diagnosis of epithelial ovarian carcinoma.
Insights
Circulating autoantibodies (AAbs) targeting tumor-associated antigens (TAAs) show promise for early epithelial ovarian carcinoma detection. Identifying these AAbs could lead to novel diagnostic tools for this cancer.
Area of Science:
- Oncology
- Immunology
- Biomarkers
Background:
- Epithelial ovarian carcinoma diagnosis often occurs at late stages.
- Circulating autoantibodies (AAbs) against tumor-associated antigens (TAAs) are increasingly recognized in cancer patients.
Purpose of the Study:
- To review recent knowledge on circulating AAbs to TAAs in epithelial ovarian carcinoma.
- To explore the potential of AAbs as early diagnostic biomarkers for epithelial ovarian carcinoma.
Main Methods:
- Literature review of studies identifying TAAs and associated AAbs in epithelial ovarian carcinoma.
- Analysis of identified TAAs including p53, HOX proteins, HSPs, MUC1, and others.
Main Results:
- Several TAAs eliciting circulating AAbs in epithelial ovarian carcinoma have been identified.
- AAbs to TAAs like p53, HOXA7, HOXB7, HSP-27, HSP-90, cathepsin D, NY-ESO-1/LAGE-1, MUC1, GIPC-1, IL-8, Ep-CAM, and S100A7 are found in patients.
- AAbs are detectable even in early-stage disease.
Conclusions:
- A panel of AAbs specific for epithelial ovarian carcinoma TAAs may serve as a novel tool for early diagnosis.
- Further research into AAb panels could significantly improve early detection rates for epithelial ovarian carcinoma.
